Barclays Lowers Chemours (NYSE:CC) Price Target to $13.00

Chemours (NYSE:CC - Free Report) had its price target reduced by Barclays from $16.00 to $13.00 in a research report report published on Wednesday,Benzinga reports. They currently have an equal weight rating on the specialty chemicals company's stock.

Other analysts have also issued research reports about the company. BMO Capital Markets decreased their price objective on Chemours from $34.00 to $27.00 and set an "outperform" rating for the company in a report on Wednesday, February 19th. UBS Group decreased their price target on Chemours from $18.00 to $17.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. Morgan Stanley dropped their price target on Chemours from $22.00 to $15.00 and set an "equal weight" rating on the stock in a research note on Monday, May 12th. Royal Bank of Canada decreased their price objective on shares of Chemours from $17.00 to $14.00 and set an "outperform" rating for the company in a research report on Thursday, May 8th. Finally, Wall Street Zen cut shares of Chemours from a "hold" rating to a "sell" rating in a research note on Wednesday, May 21st. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $17.22.

Chemours Stock Up 0.4%

Shares of CC stock traded up $0.04 during mid-day trading on Wednesday, hitting $10.15. 5,382,386 shares of the stock traded hands, compared to its average volume of 2,143,667. Chemours has a 52-week low of $9.33 and a 52-week high of $25.80. The stock has a market cap of $1.52 billion, a P/E ratio of 17.81 and a beta of 1.76. The company has a debt-to-equity ratio of 6.70, a current ratio of 1.68 and a quick ratio of 0.92. The stock's fifty day moving average is $11.55 and its two-hundred day moving average is $15.65.

Chemours (NYSE:CC - Get Free Report) last posted its earnings results on Tuesday, May 6th. The specialty chemicals company reported $0.13 EPS for the quarter, missing analysts' consensus estimates of $0.19 by ($0.06). The firm had revenue of $1.37 billion for the quarter, compared to analysts' expectations of $1.36 billion. Chemours had a net margin of 1.51% and a return on equity of 26.54%. The company's revenue was up .4% on a year-over-year basis. During the same period in the previous year, the company earned $0.32 EPS. Equities analysts predict that Chemours will post 2.03 EPS for the current year.

Chemours Dividend Announcement

The firm also recently disclosed a dividend, which will be paid on Monday, June 16th. Stockholders of record on Monday, May 19th will be paid a $0.0875 dividend. The ex-dividend date of this dividend is Friday, May 16th. This represents a dividend yield of 3.17%. Chemours's payout ratio is currently 175.00%.

Insider Buying and Selling

In related news, CFO Shane Hostetter acquired 4,450 shares of the stock in a transaction on Monday, May 19th. The shares were acquired at an average price of $11.28 per share, for a total transaction of $50,196.00. Following the transaction, the chief financial officer now owns 59,694 shares in the company, valued at approximately $673,348.32. This trade represents a 8.06% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.34% of the stock is currently owned by corporate insiders.

Institutional Trading of Chemours

Hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its holdings in Chemours by 8.3% in the first quarter. Vanguard Group Inc. now owns 16,487,008 shares of the specialty chemicals company's stock valued at $223,069,000 after buying an additional 1,263,047 shares in the last quarter. Ameriprise Financial Inc. grew its position in shares of Chemours by 23.8% during the 4th quarter. Ameriprise Financial Inc. now owns 4,373,172 shares of the specialty chemicals company's stock valued at $73,907,000 after acquiring an additional 839,849 shares during the period. Millennium Management LLC grew its position in shares of Chemours by 60.4% during the 1st quarter. Millennium Management LLC now owns 4,022,782 shares of the specialty chemicals company's stock valued at $54,428,000 after acquiring an additional 1,515,520 shares during the period. American Century Companies Inc. increased its stake in shares of Chemours by 17.5% in the 1st quarter. American Century Companies Inc. now owns 1,909,149 shares of the specialty chemicals company's stock valued at $25,831,000 after purchasing an additional 284,130 shares in the last quarter. Finally, Norges Bank purchased a new position in shares of Chemours in the 4th quarter valued at about $30,702,000. 76.26% of the stock is owned by hedge funds and other institutional investors.

About Chemours

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.